Andere talen SpectraCure AB

Aandelen

SPEC

SE0007158118

Beurs gesloten - Nasdaq Stockholm Andere beurzen 18:00:00 02-07-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,445 ^SEK	-2,00%		+1,66%	-36,66%

16/05	SpectraCure AB (publ) rapporteert resultaten voor het eerste kwartaal afgesloten op 31 maart 2024	CI
23/02	Spectracure AB (Publ) gaat verder met het opstarten van een klinische studie voor primair gelokaliseerde prostaatkanker	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

SpectraCure AB Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05
SpectraCure takes the next step in the work with the new clinical study	23/02
Spectracure AB Continues in the Process of Initiating A Clinical Study, for Primary Localised Prostate Cancer	23/02
SpectraCure AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	22/02
A well-accomplished annual audit in accordance with ISO 13485:2016	23/01
Expert group comments on results of ongoing study	19/12
SpectraCure AB Conducts a Clinical Study for Patients with Recurrence of Prostate Cancer After Radiotherapy	19/12
SpectraCure : Masoud Khayyami presents SpectraCure at investor meetingon November 5 in Lund!	29/11
SpectraCure AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	16/11
SpectraCure has decided to seek approval for a clinical study of primary prostate cancer	16/11
SpectraCure AB Decides to Seek Approval for Clinical Study of Primary Prostate Cancer	16/11
SpectraCure : Meet SpectraCure’s board member, Homer Pien!	31-10-23
SpectraCure strengthens presence among urologists	06-10-23
SpectraCure AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	17-08-23
SpectraCure has been awarded an additional EU grant for industrialisation of the company's treatment system Q-PRO®	27-06-23
SpectraCure Receives an Additional EU Grant	27-06-23
SpectraCure AB Reports Earnings Results for the First Quarter Ended March 31, 2023	16-05-23
SpectraCure AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	22-02-23
SpectraCures signs Letter of Intent with Cheplapharm	07-12-22
SpectraCures Signs Letter of Intent with Cheplapharm	07-12-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen SpectraCure AB

Aandelen

SPEC

SE0007158118

Andere talen

Filters